Submission Details
| 510(k) Number | K230796 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | March 22, 2023 |
| Decision Date | June 20, 2023 |
| Days to Decision | 90 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
K230796 is an FDA 510(k) clearance for the Sparrow Ascent, a Percutaneous Nerve Stimulator For Opioid Withdrawal (Class II — Special Controls, product code PZR), submitted by Spark Biomedical, Inc. (Dallas, US). The FDA issued a Cleared decision on June 20, 2023, 90 days after receiving the submission on March 22, 2023. This device falls under the Neurology review panel. Regulated under 21 CFR 882.5896.
| 510(k) Number | K230796 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | March 22, 2023 |
| Decision Date | June 20, 2023 |
| Days to Decision | 90 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
| Product Code | PZR — Percutaneous Nerve Stimulator For Opioid Withdrawal |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 882.5896 |
| Definition | Stimulate Nerve Branches To Aid In The Reduction Of Symptoms Associated With Substance Use Disorders. |